Impact of Dyspnea, Regional Lung Ventilation, and Diaphragmatic Function During de Novo Acute Respiratory Failure
DY-VI-DI
Evaluation of Dyspnea, Pulmonary VentIlation and DIaphragmatic Function in de Novo Adult Acute Respiratory Failure.
1 other identifier
observational
55
1 country
1
Brief Summary
Modern management of acute respiratory failure aims to relieve dyspnea and anxiety by providing a non-invasive respiratory support. This approach tries to avoid endotracheal intubation, patient self inflicted lung injuries (PSILI) and diaphragmatic dysfunction. The present study aims to evaluate dyspnea, pulmonary regional ventilation and diaphragmatic function in patients with hypoxemic acute respiratory failure by different observations, and to bring risk factor for intubation out.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 18, 2021
CompletedFirst Posted
Study publicly available on registry
July 14, 2021
CompletedStudy Start
First participant enrolled
August 11, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 22, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 22, 2025
CompletedMarch 6, 2026
March 1, 2026
3.9 years
June 18, 2021
March 5, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Oro-tracheal intubation
Patients who will be intubated within the 7 days after admission in the ICU
7 days after admission in the ICU
Secondary Outcomes (8)
Diaphragmatic function
2 days after inclusion
Diaphragmatic function
2 days after inclusion
lung regional ventilation
2 days after inclusion
Dyspnea evaluation
28 days after inclusion
Dyspnea evaluation
28 days after inclusion
- +3 more secondary outcomes
Study Arms (1)
Patients with de novo acute respiratory failure
The following tests will be performed as part of the research (these tests are usually performed as part of routine care but not routinely and comprehensively): * A diaphragmatic ultrasound in the half-seated position. Diaphragmatic excursion and thickening fraction will be measured in the right hemi-diaphragm. * A 10-minute reference acquisition. They will be performed at inclusion, H2, H4 and H48.
Interventions
A diaphragmatic ultrasound in a half sitting position. The diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm will be measured. \- Acquisition of 10 minutes of regional pulmonary ventilation by electrical impedance tomography.
Eligibility Criteria
Patients with de novo acute respiratory failure
You may qualify if:
- Age \> 18
- Acute respiratory insufficiency defined by the three following items :
- PaO2/ FiO2 \<300
- Respiratory rate \> 25/min
- Oxygen support \> 10L/min or High Flow nasal oxygen (HFNO)
- Non opposition by the patient to be included
- Social insurance
You may not qualify if:
- Respiratory acidosis (pH \< 7,35 PaCO2 \> 45mmHg or 6kPa)
- Chronic respiratory disease ( COPD, bronchiectasis…)
- Cardiogenic Acute lung oedema
- Non intubation decision at randomisation
- Contraindication for Electro-impedance tomography-belt placement (chest trauma with rib fractures, thoracic wound, chest tube).
- Uncommunicative patient (Glasgow coma scale \<12)
- Guardianship or curators for vulnerable patients.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Groupe Hospitalier Pitié-Salpêtrière", Intensive care unit
Paris, 75013, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Martin DRES, MD PhD
Assistance Publique - Hôpitaux de Paris
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 18, 2021
First Posted
July 14, 2021
Study Start
August 11, 2021
Primary Completion
July 22, 2025
Study Completion
July 22, 2025
Last Updated
March 6, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF
- Time Frame
- Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
- Access Criteria
- Researchers who provide a methodologically sound proposal.
The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.